The Acute Effect of Intermittent Pneumatic Foot Compression on Antiplasmin, Plasminogen Activator Inhibitor, Tissue Factor Pathway Inhibitor, Tissue Plasminogen Activator, and von Willebrand Factor

2018 ◽  
Vol 6 (2) ◽  
pp. 284
Author(s):  
Osama Albazde ◽  
Christopher R. Lattimer ◽  
Jeff Jean-Marie ◽  
Jawed Fareed ◽  
George Geroulakos
Keyword(s):  
Plasminogen Activator ◽  
Von Willebrand Factor ◽  
Tissue Factor Pathway Inhibitor ◽  
Plasminogen Activator Inhibitor ◽  
Acute Effect ◽  
Tissue Plasminogen ◽  
Tissue Factor Pathway ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Activator Inhibitor

von Willebrand Factor, Soluble P-Selectin, Tissue Plasminogen Activator and Plasminogen Activator Inhibitor in Atherosclerosis

1995 ◽  
Vol 74 (02) ◽  
pp. 626-630 ◽  
Author(s):  
A D Blann ◽  
M Dobrotova ◽  
P Kubisz ◽  
C N McCollum
Keyword(s):  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Von Willebrand Factor ◽  
Plasminogen Activator Inhibitor ◽  
Tissue Plasminogen ◽  
Soluble P ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Activator Inhibitor ◽  
Pai 1

SummaryTissue plasminogen activator antigen (tPA), plasminogen activator inhibitor antigen (PAI-1), soluble P-selectin and von Willebrand factor antigen (vWf) were measured by ELISA in 41 patients with peripheral vascular disease (PVD), 41 with ischaemic heart disease (IHD) and in 46 age and sex matched asymptomatic controls. Increased vWf was found in patients with IHD (p = 0.0002) and in patients with PVD (p = 0.0011) relative to the controls but levels did not differ between the two patients groups. Raised tPA found in both PVD (p = 0.0006) and IHD (p = 0.0061) compared to the controls also failed to differentiate the two groups of patients. Soluble P-selectin was also raised in both groups (p = 0.003 in IHD and p = 0.0102 in PVD) with no difference between the groups. There were no differences in levels of PAI-1 between the groups. In the subjects taken as a whole, there were significant Spearman’s correlations between tPA and vWf (r = 0.37, p <0.001), tPA and triglycerides (r = 0.38, p <0.001), tPA and P-selectin (r = 0.19, p = 0.032), vWf and age (r = 0.25, p = 0.005) and inversely between vWf and HDL (r = -0.25, p = 0.006). These data support the concept that increased levels of tPA may be important in atherosclerosis, and indicate that soluble P-selectin may be useful in further analysis of the role of platelets and the endothelial cell in this disease.

Von Willebrand Factor, Plasminogen Activator Inhibitor-1 and C-Reactive Protein Are Markers of Thrombolytic Efficacy in Acute Myocardial Infarction

1992 ◽  
Vol 68 (06) ◽  
pp. 678-682 ◽  
Author(s):  
F Andreotti ◽  
D R Hackett ◽  
A W Haider ◽  
M C Roncaglioni ◽  
G J Davies ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Plasminogen Activator ◽  
Von Willebrand Factor ◽  
Plasminogen Activator Inhibitor ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Activator Inhibitor

SummaryPlasma von Willebrand factor, plasminogen activator inhibitor activity and C-reactive protein were assessed as markers of coronary recanalisation in 30 patients with acute myocardial infarction receiving tissue-type plasminogen activator (t-PA). Blood samples were taken before t-PA (time 0), 4-hourly for 24 h and daily up to 72 h. A continuous electrocardiogram was recorded in the first 24 h. Coronary arteriography was performed 90 min and 24 h after the start of t-PA. Patients with a patent infarct artery (n = 17), compared to those with occluded artery (n = 13), showed a fall in von Willebrand factor from 0 to 24 h (p = 0.001), a greater fall in plasminogen activator inhibitor from 24 to 48 h (p = 0.04) and a fall in C-reactive protein from 48 to 72 h (p = 0.002). The accuracy of these indices compared favourably with time to peak plasma MB creatine kinase and ≥ 50% resolution of maximal ST-deviation on the electrocardiogram.Thus, changes in plasma von Willebrand factor, plasminogen activator inhibitor and C-reactive protein during the first 3 days of myocardial infarction are indicative of thrombolytic efficacy. Their concordant behaviour may reflect a common regulatory mechanism.

Increase in Plasma Concentrationof Plasminogen Activator Inhibitor, Fibrinogen, von Willebrand Factor, Factor VIII: Cand in Erythrocyte Sedimentation Rate with Age

1986 ◽  
Vol 55 (03) ◽  
pp. 330-332 ◽  
Author(s):  
M F Aillaud ◽  
F Pignol ◽  
M C Alessi ◽  
J R Harle ◽  
M Escande ◽  
...  
Keyword(s):  
Plasma Concentration ◽  
Plasminogen Activator ◽  
Von Willebrand Factor ◽  
Sedimentation Rate ◽  
Acute Phase Proteins ◽  
Plasminogen Activator Inhibitor ◽  
Erythrocyte Sedimentation ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Activator Inhibitor

SummaryElderly patients have previously been shown to have an increased plasma concentration of tissue plasminogen activator (t-PA) antigen (t-PAAg). Since the concentration of t-PA Ag dependson both free t-PA and t-PA complexed with inhibitors, mainly plasminogen activator inhibitor (PA inhibitor), we have investigated the relationship between the plasma concentration of PA inhibitor and age in 20 elderly and 20 young individuals. Elderly individuals showed a slight increase in PA inhibitor, in parallel with increase on others, acute-phase proteins, fibrinogen, von Willebrand factor, factor VIII :C, and the erythrocyte sedimentation rate. The increase i PA inhibitor as well as other acute-phase proteins in the elderly may be significant in relation to the increased incidence of thrombotic disease.

Imbalance of Plasminogen Activator Inhibitor-I/ Tissue Plasminogen Activator and Tissue Factor/Tissue Factor Pathway Inhibitor in Young Japanese Men with Myocardial Infarction

2001 ◽  
Vol 86 (11) ◽  
pp. 1197-1203 ◽  
Author(s):  
Masahiko Saigo ◽  
Masakazu Ogawa ◽  
Tsuminori Yamashita ◽  
Sadatoshi Biro ◽  
Shinichi Minagoe ◽  
...  
Keyword(s):  
Tissue Factor ◽  
Plasminogen Activator ◽  
Protein C ◽  
Tissue Factor Pathway Inhibitor ◽  
Antithrombin Iii ◽  
Plasminogen Activator Inhibitor ◽  
Lipoprotein A ◽  
Tissue Plasminogen ◽  
Tissue Factor Pathway ◽  
Activator Inhibitor

SummaryTo evaluate the association between haemostatic parameters and increased risk of myocardial infarction (MI) at a young age, we measured fibrinogen, factor VII, antithrombin III, protein C, protein S, tissue factor (TF), free form tissue factor pathway inhibitor (TFPI), plasminogen, 2-antiplasmin, tissue plasminogen activator (tPA), plasminogen activator inhibitor-I (PAI-I), and lipoprotein (a) in 140 young men with MI before age 45 and 150 age-matched healthy men. TF, TF/TFPI ratio, PAI-I, PAI-I/tPA ratio, plasminogen, and lipoprotein (a) in young MI patients were all significantly higher than controls, while TFPI, antithrombin III, and tPA were significantly lower (P <0.001 of each). Significant determinants of MI risk were PAI-I/tPA ratio (R2 = 0.300, P <0.001), TF/TFPI ratio (R2 = 0.049, P <0.001), antithrombin III (R2 = 0.034, P <0.001), hyperlipidaemia (R2 = 0.019, P = 0.004), diabetes (R2 = 0.014, P = 0.015), lipoprotein (a) (R2 = 0.012, P = 0.023), 2-antiplasmin (R2 = 0.014, P = 0.012), and protein C (R2 = 0.012, P = 0.018). We conclude that the imbalances of PAI-I/tPA and TF/TFPI are significantly associated with MI at a young age, perhaps mediated via impaired fibrinolytic activity.

scholarly journals Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism

2009 ◽  
Vol 160 (5) ◽  
pp. 863-868 ◽  
Author(s):  
Cihangir Erem ◽  
Mustafa Kocak ◽  
İrfan Nuhoglu ◽  
Mustafa Yilmaz ◽  
Ozge Ucuncu
Keyword(s):  
Plasminogen Activator ◽  
Tissue Factor Pathway Inhibitor ◽  
Plasminogen Activator Inhibitor ◽  
Plasminogen Activator Inhibitor 1 ◽  
Thrombin Activatable Fibrinolysis Inhibitor ◽  
Tissue Plasminogen ◽  
Fibrinolysis Inhibitor ◽  
Tissue Factor Pathway ◽  
Activator Inhibitor ◽  
Pai 1

Background and objectivesPrimary hyperparathyroidism (PHPT) is associated with increased cardiovascular mortality and morbidity. Little is known about hemostatic features of patients with PHPT. To our knowledge, plasma tissue factor pathway inhibitor (TFPI) and thrombin-activatable fibrinolysis inhibitor (TAFI) levels in these patints have not been investigated. Therefore, the main purpose of this study was to evaluate the markers of endogenous coagulation/fibrinolysis, including TFPI and TAFI, and to investigate the relationships between serum calcium and PTH and these hemostatic parameters in patients with PHPT.Design and methodsTwenty-four patients with PHPT and 20 age-, sex-, and-weight-matched healthy controls were included in the study. Tissue plasminogen activator (t-PA), tissue plasminogen activator inhibitor-1 (PAI-1), TFPI, and TAFI were measured. The relationships between serum calcium, phosphorus, and PTH and these hemostatic parameters were examinated.ResultsCompared with the control subjects, t-PA, PAI-1, and PAI-1/t-PA ratios were significantly increased in patients with PHPT (P<0.0001), whereas TFPI levels were significantly decreased (P<0.0001). Plasma TAFI Ag levels did not significantly change in patients with PHPT compared with the controls. In patients with PHPT, serum phosphorus was negatively correlated with plasma PAI-1 Ag levels and PAI-1/t-PA ratio (r: −0.453,P<0.05;r: −0.580,P<0.01 respectively). There was a positive correlation between Cl/P ratio and plasma PAI-1 levels and PAI-1/t-PA ratio (r: 0.434,P<0.05;r: 0.528,P<0.05 respectively). iPTH was positively correlated with plasma PAI-1/t-PA ratio (r: 0.429,P<0.05).Interpretation and conclusionsIn conclusion, we found some important differences in the hemostatic parameters between the patients with PHPT and healthy controls. Increased PAI-1, PAI-1/t-PA ratios and decreased TFPI levels in these patients represent a potential hypercoagulable and hypofibrinolytic state, which might augment the risk for atherosclerotic and atherothrombotic complications. This condition may contribute to the excess mortality due to cardiovascular disease seen in patients with PHPT.

Sign in / Sign up

Export Citation Format

Share Document